WEBVTT

00:00:00.000 --> 00:00:02.480
Welcome back to the Deep Dive. This is where

00:00:02.480 --> 00:00:05.599
we take that really dense source material, you

00:00:05.599 --> 00:00:07.639
know, the strategic reports, the deep research,

00:00:07.799 --> 00:00:09.980
and we try to distill it down into something

00:00:09.980 --> 00:00:12.699
you can actually use. Exactly. We're giving you

00:00:12.699 --> 00:00:15.519
the shortcut to understanding the complex blueprint

00:00:15.519 --> 00:00:18.320
behind some of these major industry players.

00:00:18.620 --> 00:00:21.649
And today... We have a really fascinating one,

00:00:21.750 --> 00:00:24.890
a company called Biotechnique Corporation. Right.

00:00:25.109 --> 00:00:27.850
Now, that name might not ring a bell for everyone

00:00:27.850 --> 00:00:30.929
outside of, say, the science community, but their

00:00:30.929 --> 00:00:32.689
products, their high -tech instruments, they

00:00:32.689 --> 00:00:36.030
are absolutely foundational to modern life sciences.

00:00:36.710 --> 00:00:38.570
Foundational is the right word. I mean, biotechnology

00:00:38.570 --> 00:00:41.329
development, advanced clinical diagnostics all

00:00:41.329 --> 00:00:43.829
over the world. They are really the definition

00:00:43.829 --> 00:00:46.210
of an essential infrastructure provider. That's

00:00:46.210 --> 00:00:49.869
right. And our mission today is, I think, pretty

00:00:49.869 --> 00:00:53.270
ambitious. We're moving way beyond a simple corporate

00:00:53.270 --> 00:00:55.390
biography. We're not just reading off a list

00:00:55.390 --> 00:00:57.670
of products. No. We want to extract the underlying

00:00:57.670 --> 00:01:00.469
strategy, the almost audacious plan that let

00:01:00.469 --> 00:01:02.909
this company, which trades as tech on NASDAQ,

00:01:02.990 --> 00:01:06.069
by the way, transform itself from a small regional

00:01:06.069 --> 00:01:09.530
supplier founded back in the 70s. Into a massive

00:01:09.530 --> 00:01:13.250
global. S &P 500 component. I mean, we're talking

00:01:13.250 --> 00:01:15.709
well over a billion dollars in annual revenue.

00:01:15.790 --> 00:01:18.469
It's an incredible story. And the hook, the really

00:01:18.469 --> 00:01:20.609
surprising part, is how they did it. It really

00:01:20.609 --> 00:01:23.189
is. Because when you look at their 2025 financial

00:01:23.189 --> 00:01:26.670
snapshot, U .S. dollar, 1 .22 billion in revenue,

00:01:26.870 --> 00:01:31.129
assets at 2 .56 billion, over 3 ,100 employees

00:01:31.129 --> 00:01:35.650
globally. just screams stability. Right. Market

00:01:35.650 --> 00:01:38.189
dominance. Exactly. But then you rewind the clock,

00:01:38.310 --> 00:01:40.829
you look at the timeline from about 2013 onwards,

00:01:40.930 --> 00:01:45.049
and the surprise is the sheer volume, the velocity

00:01:45.049 --> 00:01:47.629
of the acquisition. It's relentless. Completely.

00:01:47.769 --> 00:01:50.310
The highly targeted strategic acquisitions are

00:01:50.310 --> 00:01:52.590
what actually built this giant. It is, I would

00:01:52.590 --> 00:01:54.750
argue, the most aggressive growth by acquisition

00:01:54.750 --> 00:01:57.189
story in life sciences in the last decade. It's

00:01:57.189 --> 00:01:59.189
a blueprint for buying market share and technology

00:01:59.189 --> 00:02:01.489
at the same time. So before we dive into that

00:02:01.489 --> 00:02:03.129
acquisition spree, let's just... establish what

00:02:03.129 --> 00:02:06.189
biotechny actually sells good idea so our sources

00:02:06.189 --> 00:02:08.949
say they develop manufacture and sell life science

00:02:08.949 --> 00:02:11.870
reagents so the consumables the consumables right

00:02:11.870 --> 00:02:14.669
also instruments the machines and services but

00:02:14.669 --> 00:02:17.349
the key is they segment the market into three

00:02:17.349 --> 00:02:20.169
very specific areas and we need to keep this

00:02:20.169 --> 00:02:22.870
three -pronged focus in mind because it explains

00:02:22.870 --> 00:02:25.530
every purchase they made it does so number one

00:02:25.530 --> 00:02:27.889
is the research market number two the diagnostic

00:02:27.889 --> 00:02:31.990
market and three The bioprocessing market. Okay,

00:02:32.050 --> 00:02:35.090
so research, diagnostic, bioprocessing. Understanding

00:02:35.090 --> 00:02:37.430
those three segments is, well, it's the master

00:02:37.430 --> 00:02:40.069
key to their whole M &A strategy. The research

00:02:40.069 --> 00:02:43.250
market is your academic labs, early pharma, R

00:02:43.250 --> 00:02:46.669
&D. They need specialized, high -quality stuff.

00:02:46.830 --> 00:02:48.889
And the diagnostic market. That demands regulated,

00:02:49.050 --> 00:02:51.610
super -reliable instruments and controls for

00:02:51.610 --> 00:02:53.610
clinical testing, you know, things for disease

00:02:53.610 --> 00:02:56.750
monitoring, screening. Okay, and bioprocessing

00:02:56.750 --> 00:02:59.710
is the big scale -up stuff. That's it. Companies

00:02:59.710 --> 00:03:01.949
manufacturing things like monoclonal antibodies

00:03:01.949 --> 00:03:04.610
or gene therapies, they need bulk materials,

00:03:04.689 --> 00:03:07.530
certified and really robust high throughput instruments.

00:03:08.770 --> 00:03:11.210
Biotechnae just systematically bought companies

00:03:11.210 --> 00:03:13.129
that served all three. So they're not just selling

00:03:13.129 --> 00:03:15.930
test tubes. Not at all. They're selling the foundational

00:03:15.930 --> 00:03:19.129
tools for every single stage of modern medicine.

00:03:19.469 --> 00:03:22.250
OK, let's unpack this history. You can't really

00:03:22.250 --> 00:03:24.270
get the pivot without knowing where they started

00:03:24.270 --> 00:03:26.990
from. Right. The genesis of this company. goes

00:03:26.990 --> 00:03:30.930
all the way back to 1976, founded by a Roger

00:03:30.930 --> 00:03:33.550
C. Lucas in Minneapolis, Minnesota. And that

00:03:33.550 --> 00:03:37.430
date, 1976, is important. It puts them right

00:03:37.430 --> 00:03:40.229
at the dawn of the modern biotech era. We're

00:03:40.229 --> 00:03:42.669
talking early genetic engineering, molecular

00:03:42.669 --> 00:03:45.569
biology. And the original name is a huge clue,

00:03:45.669 --> 00:03:47.469
isn't it? Oh, it's profoundly important. They

00:03:47.469 --> 00:03:49.650
were called Research and Diagnostic Systems,

00:03:49.930 --> 00:03:53.449
Inc. So no ambiguity there. None at all. It immediately

00:03:53.449 --> 00:03:56.169
defined their function, supplying materials for...

00:03:56.169 --> 00:03:58.849
research and for clinical diagnostics. They carved

00:03:58.849 --> 00:04:01.229
out their niche really early, focusing on quality.

00:04:01.509 --> 00:04:03.789
So they had that foundation from the start. Yeah.

00:04:03.849 --> 00:04:06.629
But the first big structural shift, the one that

00:04:06.629 --> 00:04:08.330
set them up for this aggressive growth later

00:04:08.330 --> 00:04:10.969
on, that came in 1985. Almost a decade later,

00:04:11.090 --> 00:04:12.770
yeah. That's when research and diagnostic systems

00:04:12.770 --> 00:04:15.870
merged and they became Techni Corporation. And

00:04:15.870 --> 00:04:19.230
that 1985 merger was the pivotal structural moment.

00:04:19.350 --> 00:04:21.709
It wasn't just, you know, a new name on the letterhead.

00:04:21.790 --> 00:04:23.850
No, it was how they went public. Exactly. It

00:04:23.850 --> 00:04:26.170
transitioned them into a public company listing

00:04:26.170 --> 00:04:29.250
on Nasdaq as tech. And this matters so much because

00:04:29.250 --> 00:04:31.550
becoming public established the financial architecture.

00:04:31.850 --> 00:04:34.009
The ability to raise money. The ability to raise

00:04:34.009 --> 00:04:37.829
money, access huge pools of funding, and critically,

00:04:38.050 --> 00:04:41.389
the ability to use company stock as currency

00:04:41.389 --> 00:04:43.490
for all those acquisitions that would come later.

00:04:43.629 --> 00:04:47.029
Right. Without that 1985 IPO, the 2013 hyper

00:04:47.029 --> 00:04:49.029
growth period just couldn't have happened. It

00:04:49.029 --> 00:04:50.569
couldn't have been financed, not at that speed.

00:04:50.790 --> 00:04:52.990
So now we fast forward almost three decades.

00:04:53.250 --> 00:04:56.430
We're at 2013, 2014, and this is where the real

00:04:56.430 --> 00:04:58.769
strategic pivot begins. Driven by a leadership

00:04:58.769 --> 00:05:01.730
change. Right. In March 2013, Charles, everyone

00:05:01.730 --> 00:05:04.029
calls him Chuck Cometh, was named the CEO and

00:05:04.029 --> 00:05:06.189
director of what was still called Techni Corporation.

00:05:06.730 --> 00:05:09.529
And this change is the starting gun for the whole

00:05:09.529 --> 00:05:12.370
new era. When you bring in a new CEO with a mandate

00:05:12.370 --> 00:05:15.310
for growth, it signals something is about to

00:05:15.310 --> 00:05:17.370
happen. And it happened fast. Cometh arrives

00:05:17.370 --> 00:05:21.910
in March 2013. And the first major nine -figure

00:05:21.910 --> 00:05:24.670
acquisition happens that same year, just a few

00:05:24.670 --> 00:05:27.430
months later. It's incredible timing. It feels

00:05:27.430 --> 00:05:29.930
like the strategy was already in place. But the

00:05:29.930 --> 00:05:32.350
formal announcement, the rebranding, came a bit

00:05:32.350 --> 00:05:36.310
later. February 2014. Almost a year after the

00:05:36.310 --> 00:05:38.750
CEO. That's when the name officially changed

00:05:38.750 --> 00:05:40.949
from this sort of generic techne corporation

00:05:40.949 --> 00:05:45.269
to the much more powerful. sector -specific biotechnology.

00:05:45.470 --> 00:05:47.829
And what's so fascinating is that time gap. The

00:05:47.829 --> 00:05:50.329
sequencing of events tells you so much. How so?

00:05:50.550 --> 00:05:54.050
Well, you have the new CEO in March 2013, then

00:05:54.050 --> 00:05:56.970
the first massive strategic action, the apposition

00:05:56.970 --> 00:06:01.310
of bionostics for $104 million cash. Happens

00:06:01.310 --> 00:06:03.670
just four months later in July. A huge commitment

00:06:03.670 --> 00:06:05.509
right out of the gate. A massive commitment to

00:06:05.509 --> 00:06:08.329
diagnostics. It signaled their new intent. And

00:06:08.329 --> 00:06:10.310
only after they demonstrated this new direction

00:06:10.310 --> 00:06:12.889
with aggressive action did they formalize the

00:06:12.889 --> 00:06:15.089
identity with the rebranding. So the name change

00:06:15.089 --> 00:06:17.629
from Techni to Biotechni wasn't just some marketing

00:06:17.629 --> 00:06:20.089
exercise. Not at all. It was a public confirmation

00:06:20.089 --> 00:06:22.810
of a pivot that was already happening financially

00:06:22.810 --> 00:06:25.980
and operationally. Precisely. It was a laser

00:06:25.980 --> 00:06:29.800
focus, shedding any ambiguity. They aligned their

00:06:29.800 --> 00:06:32.800
name with the highest growth sectors, life sciences,

00:06:33.060 --> 00:06:36.339
biotech, technology integration. It was a message

00:06:36.339 --> 00:06:39.160
to the market, to investors and to future acquisition

00:06:39.160 --> 00:06:42.199
targets. A message that said, we are all in.

00:06:42.259 --> 00:06:45.560
All in on biology and technology across research,

00:06:45.779 --> 00:06:48.360
diagnostics and bioprocessing. That name change

00:06:48.360 --> 00:06:50.720
really kicks off the core story we're here for.

00:06:50.879 --> 00:06:53.860
The transformation through M &A between... 2013

00:06:53.860 --> 00:06:56.759
and 2023. I mean, we are looking at a hyper aggressive.

00:06:57.519 --> 00:06:59.839
decade -long growth period. And it was driven

00:06:59.839 --> 00:07:02.079
almost entirely by these targeted acquisitions,

00:07:02.100 --> 00:07:05.000
not slow organic growth. The pace is just relentless.

00:07:05.180 --> 00:07:07.379
It really is. And our sources list, what, well

00:07:07.379 --> 00:07:09.740
over a dozen key acquisitions in that period.

00:07:09.980 --> 00:07:12.540
Each one wasn't random. They all fit into a specific

00:07:12.540 --> 00:07:15.060
strategic bucket. Like consolidating supply chain.

00:07:15.199 --> 00:07:17.639
Right. Or acquiring cutting -edge IP. Or, and

00:07:17.639 --> 00:07:19.639
this is the big one, moving the company up the

00:07:19.639 --> 00:07:22.040
value chain from just a regent supplier to a

00:07:22.040 --> 00:07:24.420
sophisticated instrument provider. Let's start

00:07:24.420 --> 00:07:27.550
with that early focus on diagnostics. Right after

00:07:27.550 --> 00:07:31.290
Cometh took over, the bionostics deal, $104 million,

00:07:31.730 --> 00:07:37.069
all cash, in July 2013. Why lead was such a huge

00:07:37.069 --> 00:07:39.730
bet on diagnostics? Well, it was a strategic

00:07:39.730 --> 00:07:42.529
declaration. It was meant to reshape the company's

00:07:42.529 --> 00:07:45.959
revenue profile immediately. Diagnostics, especially

00:07:45.959 --> 00:07:48.800
things like quality control and calibration materials,

00:07:49.120 --> 00:07:51.259
which is what bionostics did. It's a more stable

00:07:51.259 --> 00:07:54.620
revenue stream. Much more stable. It's less cyclical

00:07:54.620 --> 00:07:57.360
than selling reagents to academic labs where

00:07:57.360 --> 00:08:00.199
funding can go up and down. So dropping $104

00:08:00.199 --> 00:08:02.600
million in cash on bionostics showed they were

00:08:02.600 --> 00:08:04.500
serious about the regulated clinical market.

00:08:04.699 --> 00:08:06.120
And they doubled down on that later. They did.

00:08:06.279 --> 00:08:08.600
Two years later, they acquired Clinica Corporation

00:08:08.600 --> 00:08:12.939
in June 2015, which also bolstered that diagnostics

00:08:12.939 --> 00:08:15.720
portfolio. focusing on quality control. So they

00:08:15.720 --> 00:08:17.480
weren't just buying the tests themselves, they

00:08:17.480 --> 00:08:19.339
were buying the quality assurance systems that

00:08:19.339 --> 00:08:22.279
make those tests reliable. Exactly. That creates

00:08:22.279 --> 00:08:24.180
a really high barrier to entry for competitors.

00:08:24.620 --> 00:08:26.939
They're positioning themselves as essential partners

00:08:26.939 --> 00:08:29.399
to clinical labs. But while they were building

00:08:29.399 --> 00:08:31.980
up diagnostics, they didn't neglect their core

00:08:31.980 --> 00:08:34.440
research market. No, they were simultaneously

00:08:34.440 --> 00:08:37.860
expanding their foundational toolkit regents

00:08:37.860 --> 00:08:40.139
and antibodies. I mean, that's the absolute bread

00:08:40.139 --> 00:08:42.519
and butter of molecular biology labs everywhere.

00:08:42.840 --> 00:08:44.559
And this is where that consolidation strategy

00:08:44.559 --> 00:08:47.379
really comes into play. They just identified

00:08:47.379 --> 00:08:49.950
key players and bought them out. The perfect

00:08:49.950 --> 00:08:53.889
example is Novus Biologicals, July 2014, for

00:08:53.889 --> 00:08:58.049
$60 million. Novus was a respected brand, and

00:08:58.049 --> 00:09:00.389
buying them instantly bolstered Biotechnie's

00:09:00.389 --> 00:09:03.110
entire region and antibody offering. So it was

00:09:03.110 --> 00:09:05.909
a shortcut to a bigger catalog. A massive shortcut.

00:09:06.190 --> 00:09:08.809
In the life science supply world, brand reputation

00:09:08.809 --> 00:09:12.610
and catalog depth are everything. Acquiring Novus

00:09:12.610 --> 00:09:14.909
gave them a huge slice of that multi -billion

00:09:14.909 --> 00:09:17.269
dollar market overnight, without years of internal

00:09:17.269 --> 00:09:19.429
development. And it wasn't just one. big purchase.

00:09:19.649 --> 00:09:22.950
They kept going with smaller, more targeted acquisitions

00:09:22.950 --> 00:09:26.330
like Trevigen in 2017 and Atlanta Biologicals

00:09:26.330 --> 00:09:29.490
in 2018. And those smaller deals show how refined

00:09:29.490 --> 00:09:32.409
the strategy was. They were consolidating specialized

00:09:32.409 --> 00:09:35.090
supply chains to create a complete solution.

00:09:35.840 --> 00:09:39.080
Trevigen, for instance, specializes in DNA damage

00:09:39.080 --> 00:09:41.879
reagents, a high -value niche for cancer research.

00:09:42.120 --> 00:09:44.159
And Atlanta Biologicals? They specialize in the

00:09:44.159 --> 00:09:47.840
fundamentals, high -volume consumables like cell

00:09:47.840 --> 00:09:51.519
culture media. So by acquiring them, Biotechni

00:09:51.519 --> 00:09:54.019
secures a fundamental supply line for the booming

00:09:54.019 --> 00:09:56.940
bioprocessing sector. It's a two -pronged attack.

00:09:57.519 --> 00:10:00.440
Big platform buys for revenue growth and smaller

00:10:00.440 --> 00:10:03.460
region buys for supply chain control. Exactly.

00:10:03.700 --> 00:10:06.149
And we can't forget their global ambition. The

00:10:06.149 --> 00:10:08.889
acquisition of Shanghai Prime Gene Biotech Company

00:10:08.889 --> 00:10:11.730
in April 2014, that was a very specific geographic

00:10:11.730 --> 00:10:13.950
move. Oh, highly targeted. It was about getting

00:10:13.950 --> 00:10:16.490
an immediate established foothold in the massive

00:10:16.490 --> 00:10:19.389
Chinese life science market. You have to be in

00:10:19.389 --> 00:10:21.429
Asia to be a global leader. So it's a way to

00:10:21.429 --> 00:10:23.450
bypass all the usual red tape. Instantly. It

00:10:23.450 --> 00:10:25.490
lets you integrate a local supply chain and distribution

00:10:25.490 --> 00:10:27.850
network. It shows their strategy wasn't just

00:10:27.850 --> 00:10:29.370
about what they bought, but where they could

00:10:29.370 --> 00:10:31.549
sell it. So we've got these three streams of

00:10:31.549 --> 00:10:35.220
acquisition. diagnostics, core reagents, and

00:10:35.220 --> 00:10:38.000
geographic expansion. But we have to talk about

00:10:38.000 --> 00:10:40.600
the financial engineering here. Not all of these

00:10:40.600 --> 00:10:43.139
were simple cash deals. And this is such a critical

00:10:43.139 --> 00:10:45.720
point. How do you manage risk when you're buying

00:10:45.720 --> 00:10:48.960
complex, high potential, but sometimes unproven

00:10:48.960 --> 00:10:50.799
technologies? It's all in the contract structure,

00:10:50.940 --> 00:10:52.960
right? It is. The genius is the difference between

00:10:52.960 --> 00:10:55.559
a simple cash purchase and using what are called

00:10:55.559 --> 00:10:58.220
earn -out payments tied to performance milestones.

00:10:58.679 --> 00:11:01.210
And the best examples of this are Cyvec. exosome

00:11:01.210 --> 00:11:03.759
diagnostics, and a surgeon. These were not cheap.

00:11:03.940 --> 00:11:07.039
Look at the numbers. With Cyvec in 2014, it was

00:11:07.039 --> 00:11:09.960
$60 million in cash up front, but then up to

00:11:09.960 --> 00:11:12.779
an additional $135 million in earnouts. So a

00:11:12.779 --> 00:11:14.899
potential total of almost $200 million. Right.

00:11:14.980 --> 00:11:17.559
And then Exosome Diagnostics in 2018 was even

00:11:17.559 --> 00:11:20.820
more dramatic. $250 million up front, plus a

00:11:20.820 --> 00:11:23.980
staggering potential of up to $325 million in

00:11:23.980 --> 00:11:26.120
milestone payments. That's a potential total

00:11:26.120 --> 00:11:31.019
of $575 million. And Asurgen in 2021, $215 million

00:11:31.019 --> 00:11:33.840
up front, plus... up to another $105 million

00:11:33.840 --> 00:11:36.580
in milestones. So much of the purchase price

00:11:36.580 --> 00:11:40.679
is tied to future success. Isn't that a much

00:11:40.679 --> 00:11:43.580
riskier way to do a deal compared to just buying

00:11:43.580 --> 00:11:46.059
a stable company like Novus? It's actually the

00:11:46.059 --> 00:11:48.980
opposite of reckless. It's a fundamentally shrewd

00:11:48.980 --> 00:11:52.580
risk management strategy. How so? When a technology

00:11:52.580 --> 00:11:56.600
is promising, like Exosome's liquid biopsy platform,

00:11:56.919 --> 00:11:59.600
but it's Commercial success depends on, say,

00:11:59.679 --> 00:12:01.860
getting difficult regulatory approvals or hitting

00:12:01.860 --> 00:12:04.960
huge revenue targets. Biotechni is essentially

00:12:04.960 --> 00:12:07.259
hedging its bet. So they're saying we'll pay

00:12:07.259 --> 00:12:09.740
a fair price for what you are today, but the

00:12:09.740 --> 00:12:12.590
real premium is tied to what you become. Precisely.

00:12:12.590 --> 00:12:14.990
The initial cash gets the deal done. But the

00:12:14.990 --> 00:12:17.389
massive earn -out acts as an insurance policy

00:12:17.389 --> 00:12:20.090
for Biotechni. They avoid paying the full premium

00:12:20.090 --> 00:12:22.529
for just potential. And at the same time, it

00:12:22.529 --> 00:12:24.789
keeps the original team invested. Massively.

00:12:24.950 --> 00:12:27.090
It creates a huge incentive for the founders,

00:12:27.250 --> 00:12:28.909
the key scientists, to stick around and make

00:12:28.909 --> 00:12:31.110
sure those milestones are actually met. It lines

00:12:31.110 --> 00:12:33.450
everyone's financial interests. So if Exosome

00:12:33.450 --> 00:12:36.289
Diagnostics nails the FDA approval and launches

00:12:36.289 --> 00:12:38.950
a major test, the original owners get that huge

00:12:38.950 --> 00:12:42.059
payout, if it stalls. Biotechni still owns the

00:12:42.059 --> 00:12:44.720
IP, but they've avoided paying the full highest

00:12:44.720 --> 00:12:47.539
risk premium. It's brilliant. And the fact they

00:12:47.539 --> 00:12:50.200
use this structure repeatedly for their most

00:12:50.200 --> 00:12:52.860
advanced acquisitions shows it was a core part

00:12:52.860 --> 00:12:55.200
of the strategy. It shows their M &A strategy

00:12:55.200 --> 00:12:57.600
wasn't just about getting bigger. It was about

00:12:57.600 --> 00:13:00.539
intelligently managing the risk of buying companies

00:13:00.539 --> 00:13:03.279
on the scientific frontier. OK, now let's shift

00:13:03.279 --> 00:13:06.480
focus to those highest priced acquisitions, because

00:13:06.480 --> 00:13:09.000
this is the phase where Biotechni really moves

00:13:09.000 --> 00:13:12.100
beyond being just a supplier of consumables.

00:13:12.320 --> 00:13:14.620
And becomes a provider of instrument platforms

00:13:14.620 --> 00:13:17.379
and proprietary tech. And that transition is

00:13:17.379 --> 00:13:19.759
absolutely key to understanding their jump into

00:13:19.759 --> 00:13:22.779
the S &P 500. It's a crucial distinction. The

00:13:22.779 --> 00:13:25.340
market values companies that sell capital equipment

00:13:25.340 --> 00:13:28.059
and instruments much higher than those that just

00:13:28.059 --> 00:13:30.539
sell consumables. Because the instruments create

00:13:30.539 --> 00:13:33.019
a locked -in ecosystem. That's it. It's the razor

00:13:33.019 --> 00:13:36.000
and blade model. Once a lab spends $100 ,000

00:13:36.000 --> 00:13:39.220
on a specific protein symbol machine, that customer

00:13:39.279 --> 00:13:41.720
has to keep buying the specific reagents and

00:13:41.720 --> 00:13:44.539
kits from biotechnology to make it run. And this

00:13:44.539 --> 00:13:46.960
is where it gets really interesting. The investment

00:13:46.960 --> 00:13:50.509
in instrumentation. The purchase of Protein Simple

00:13:50.509 --> 00:13:55.330
in August 2014 for $300 million. A huge signal.

00:13:55.529 --> 00:13:58.509
Is a massive strategic leap. $300 million in

00:13:58.509 --> 00:14:01.970
cash right after the new CEO and rebranding.

00:14:02.009 --> 00:14:04.190
And Protein Simple brought them into high -end

00:14:04.190 --> 00:14:06.850
lab instruments and automated proteomics tools.

00:14:07.250 --> 00:14:09.850
Proteomics, the study of proteins, is the high

00:14:09.850 --> 00:14:12.129
-value application of genomics. So they went

00:14:12.129 --> 00:14:14.110
from providing the ingredients for the experiment.

00:14:14.269 --> 00:14:16.629
To providing the entire high -performance automated

00:14:16.629 --> 00:14:19.429
kitchen. It was a clear. move into high margin

00:14:19.429 --> 00:14:21.389
capital equipment. And then just three months

00:14:21.389 --> 00:14:24.230
later, the aggressive move for Cyvek. That was

00:14:24.230 --> 00:14:26.750
the deal with the huge earn -out potential. Right.

00:14:26.850 --> 00:14:28.809
And the size and structure of that deal implied

00:14:28.809 --> 00:14:31.549
they were buying another very specific high -potential

00:14:31.549 --> 00:14:33.610
platform technology. Something that promised

00:14:33.610 --> 00:14:36.350
automation. It absolutely does. Cyvek brought

00:14:36.350 --> 00:14:38.370
in a high -throughput platform for sensitive

00:14:38.370 --> 00:14:41.269
protein or biomarker analysis. It just showed

00:14:41.269 --> 00:14:43.049
their continued appetite for technologies that

00:14:43.049 --> 00:14:45.110
promised automation and standardization things

00:14:45.110 --> 00:14:48.370
that are non -negotiable for big pharma and bioprocessing.

00:14:48.490 --> 00:14:50.549
Okay, moving into the even more advanced stuff.

00:14:50.909 --> 00:14:54.509
Cell and molecular diagnostics. This is where

00:14:54.509 --> 00:14:57.210
we see the next game -changing investments. Advanced

00:14:57.210 --> 00:15:01.309
Cell Diagnostics, or ACD, in August 2016. Another

00:15:01.309 --> 00:15:06.179
big one. $250 million up front. plus 75 million

00:15:06.179 --> 00:15:09.519
impossible milestones. So what did ACD bring

00:15:09.519 --> 00:15:12.159
to the table? ACD had proprietary technology

00:15:12.159 --> 00:15:15.480
for what's called in -situ hybridization, specifically

00:15:15.480 --> 00:15:19.080
their RNAscope tech, a really powerful way to

00:15:19.080 --> 00:15:22.220
analyze genetic material like RNA directly inside

00:15:22.220 --> 00:15:24.679
cells or tissues while keeping the spatial context.

00:15:25.000 --> 00:15:27.000
Before this, you'd just grind up a tissue and

00:15:27.000 --> 00:15:29.000
lose all information about which cells were doing

00:15:29.000 --> 00:15:31.139
what. So you could see exactly where genes were

00:15:31.139 --> 00:15:33.340
being expressed. Exactly. This is invaluable

00:15:33.340 --> 00:15:35.500
for personal... personalized medicine for understanding

00:15:35.500 --> 00:15:38.019
tumors. It's moving beyond just quantifying stuff

00:15:38.019 --> 00:15:39.960
in machine to seeing where it is in a tissue

00:15:39.960 --> 00:15:42.340
sample. So if ProteinSimple gave them the tools

00:15:42.340 --> 00:15:45.259
to analyze bulk proteins, ACD gave them the site

00:15:45.259 --> 00:15:48.379
to see DNA and RNA at a cellular level. That's

00:15:48.379 --> 00:15:50.720
a great way to put it. But the acquisition that

00:15:50.720 --> 00:15:54.220
just screamed high risk, high reward was exosome

00:15:54.220 --> 00:15:57.759
diagnostics in 2018. That massive potential price

00:15:57.759 --> 00:16:02.159
tag of $575 million. Why make such an enormous

00:16:02.159 --> 00:16:03.940
bet? Well, this is where you have to understand

00:16:03.940 --> 00:16:07.000
the science. Exosomes are these tiny little vesicles,

00:16:07.080 --> 00:16:09.480
basically nanoparticles, that are released by

00:16:09.480 --> 00:16:12.080
almost all cells, including tumor cells. And

00:16:12.080 --> 00:16:13.809
they carry information. They carry molecular

00:16:13.809 --> 00:16:15.889
cargo that reflects the state of the cell they

00:16:15.889 --> 00:16:18.870
came from. Exosome Diagnostics was a pioneer

00:16:18.870 --> 00:16:22.070
in using this for liquid biopsies. Diagnostics

00:16:22.070 --> 00:16:24.250
from a simple blood draw instead of surgery.

00:16:24.450 --> 00:16:27.190
That's it. And liquid biopsies are one of the

00:16:27.190 --> 00:16:30.250
holy grails of oncology. So the promise is detecting

00:16:30.250 --> 00:16:33.570
cancer earlier, monitoring recurrence, all non

00:16:33.570 --> 00:16:36.350
-invasively. Absolutely. So Biotechni was buying

00:16:36.350 --> 00:16:38.429
a leading position in a potentially transformative

00:16:38.429 --> 00:16:41.330
technology. That huge price tag wasn't for current

00:16:41.330 --> 00:16:43.889
revenue. It was a... massive strategic bet on

00:16:43.889 --> 00:16:46.809
capturing a huge chunk of the future diagnostics

00:16:46.809 --> 00:16:49.789
market. It was an investment in pure future -facing

00:16:49.789 --> 00:16:52.169
IP. It's amazing how they're balancing these

00:16:52.169 --> 00:16:55.049
proven research tools with these highly speculative,

00:16:55.230 --> 00:16:57.789
high -reward technologies, which brings us to

00:16:57.789 --> 00:16:59.649
the acquisitions that were clearly targeting

00:16:59.649 --> 00:17:01.889
future capabilities. They're anticipating where

00:17:01.889 --> 00:17:04.009
the research funding is going to go next. Like

00:17:04.009 --> 00:17:06.450
the purchase of BMUG and Biotechnologies in June

00:17:06.450 --> 00:17:09.940
2019. A specific, timely focus on gene editing

00:17:09.940 --> 00:17:12.880
technology. You just can't be a major life science

00:17:12.880 --> 00:17:15.299
provider today without a deep involvement in

00:17:15.299 --> 00:17:18.099
gene editing and gene therapy. This was a strategic

00:17:18.099 --> 00:17:20.220
move to make sure they had the tools for that

00:17:20.220 --> 00:17:23.119
whole burgeoning field. And then a surge in ink

00:17:23.119 --> 00:17:27.019
in April 2021, another big milestone -driven

00:17:27.019 --> 00:17:29.940
deal. A surgeon reinforces the clinical molecular

00:17:29.940 --> 00:17:32.799
side of their diagnostics market. It's about

00:17:32.799 --> 00:17:35.420
high complexity regulated molecular testing for

00:17:35.420 --> 00:17:37.579
things like inherited disorders. It keeps them

00:17:37.579 --> 00:17:39.640
at the high margin end of the diagnostic spectrum.

00:17:40.039 --> 00:17:42.660
And finally, to round out this decade of M &A,

00:17:42.720 --> 00:17:46.259
two extremely high tech additions. Namacel Inc.

00:17:46.400 --> 00:17:49.940
in June 2022 and Lunafor Technologies in June

00:17:49.940 --> 00:17:53.200
2023. And these two are really the capstone of

00:17:53.200 --> 00:17:55.559
their instrument strategy. They define the next

00:17:55.559 --> 00:17:57.960
generation of their toolset. Name -a -Cell is

00:17:57.960 --> 00:18:00.819
all about single -cell analysis technology. So

00:18:00.819 --> 00:18:03.000
understanding that not all cells in a tumor are

00:18:03.000 --> 00:18:05.500
the same. Right. But it's the acquisition of

00:18:05.500 --> 00:18:08.240
LUNIFOR that's truly groundbreaking. It targets

00:18:08.240 --> 00:18:11.420
spatial biology. Spatial biology. That seems

00:18:11.420 --> 00:18:13.440
to be the big buzzword right now. Why is it so

00:18:13.440 --> 00:18:17.160
important? Well... If ACD let you see RNA inside

00:18:17.160 --> 00:18:19.799
a cell, spatial biology takes it to the ultimate

00:18:19.799 --> 00:18:22.480
level. It lets you analyze thousands of molecular

00:18:22.480 --> 00:18:25.900
targets, proteins, RNA, DNA, all at the same

00:18:25.900 --> 00:18:29.000
time, while keeping their exact location in a

00:18:29.000 --> 00:18:31.259
three -dimensional tissue structure. That level

00:18:31.259 --> 00:18:33.519
of detail is just incredible. It's critical for

00:18:33.519 --> 00:18:35.720
developing new targeted therapies, especially

00:18:35.720 --> 00:18:38.839
in cancer and neuroscience. By buying Namacel

00:18:38.839 --> 00:18:41.559
and Lunafor, Biotechni is making sure they own

00:18:41.559 --> 00:18:43.759
the instruments for the highest resolution, most

00:18:43.759 --> 00:18:46.220
cut - edge biological research platforms available

00:18:46.220 --> 00:18:48.839
it's a remarkable strategy really phase one by

00:18:48.839 --> 00:18:52.440
the basics phase two by stability phase three

00:18:52.440 --> 00:18:55.119
by the instrument platforms to lock in customers

00:18:55.119 --> 00:18:58.359
and phase four by the blueprints for the future

00:18:58.359 --> 00:19:02.460
a perfect summary and all along they kept up

00:19:02.460 --> 00:19:06.029
the global push like buying space import -export

00:19:06.029 --> 00:19:09.210
in 2016 specifically to strengthen their European

00:19:09.210 --> 00:19:11.029
leadership. Which you need if you're going to

00:19:11.029 --> 00:19:13.369
sell and service all these complex machines worldwide.

00:19:13.789 --> 00:19:16.450
Absolutely. The technology is useless if you

00:19:16.450 --> 00:19:18.390
can't get it installed and supported in those

00:19:18.390 --> 00:19:20.589
crucial European markets. Now let's look at the

00:19:20.589 --> 00:19:23.950
results of this entire decade of M &A. The 2025

00:19:23.950 --> 00:19:27.150
financial data, it tells a very clear story.

00:19:27.589 --> 00:19:30.410
A story of successful scaling and just as important,

00:19:30.509 --> 00:19:33.190
successful integration. The strategy absolutely

00:19:33.190 --> 00:19:36.339
paid off in terms of size and stability. So let's

00:19:36.339 --> 00:19:38.819
break down those key figures from the 2025 report.

00:19:39.279 --> 00:19:42.059
This is the hard evidence that this whole strategy

00:19:42.059 --> 00:19:44.940
was viable. It is. The top line number is impressive.

00:19:45.240 --> 00:19:48.099
Revenue of U .S. dollar 1 .22 billion. Hitting

00:19:48.099 --> 00:19:50.960
that billion dollar mark is huge for a specialized

00:19:50.960 --> 00:19:53.099
company like this. It shows they've captured

00:19:53.099 --> 00:19:55.519
significant market share. And their total assets

00:19:55.519 --> 00:19:58.319
are reported at 2 .56 billion dollars. Right.

00:19:58.400 --> 00:20:00.640
Which comfortably exceeds their liabilities.

00:20:00.720 --> 00:20:03.559
You see that in the 1 .92 billion in total equity.

00:20:03.720 --> 00:20:06.000
It confirms they're structurally. healthy. Okay,

00:20:06.059 --> 00:20:08.900
but I have to pause here. Revenue is high at

00:20:08.900 --> 00:20:13.119
$1 .22 billion, but the bottom line figures seem

00:20:13.119 --> 00:20:15.980
a bit modest in comparison. Operating income

00:20:15.980 --> 00:20:20.119
was $102 million and net income was $73 .4 million.

00:20:20.359 --> 00:20:22.640
That's a great question. How do you reconcile

00:20:22.640 --> 00:20:25.960
a billion in revenue with a relatively thin net

00:20:25.960 --> 00:20:28.440
profit margin? And that is the critical analytic

00:20:28.440 --> 00:20:30.920
moment. That low net income isn't necessarily

00:20:30.920 --> 00:20:33.220
a sign of inefficiency. It's the direct financial

00:20:33.220 --> 00:20:35.420
evidence of the M &A strategy we've been talking

00:20:35.420 --> 00:20:37.539
about. So it's the cost of growth. It's entirely

00:20:37.539 --> 00:20:39.220
the cost of growth. The difference between $1

00:20:39.220 --> 00:20:42.779
.22 billion in revenue and $73 .4 million in

00:20:42.779 --> 00:20:45.839
net income shows us they are heavily, heavily

00:20:45.839 --> 00:20:48.400
reinvesting. They are choosing growth and market

00:20:48.400 --> 00:20:50.799
position over short -term profit. So we're talking

00:20:50.799 --> 00:20:53.480
about massive integration costs, streamlining

00:20:53.480 --> 00:20:56.740
processes, unifying IT systems. paying off all

00:20:56.740 --> 00:20:59.019
the costs associated with dozens of acquisitions.

00:20:59.339 --> 00:21:01.859
Precisely. And the R &D burden to take a technology

00:21:01.859 --> 00:21:04.059
like Exosome Diagnostics from just a promise

00:21:04.059 --> 00:21:06.140
to a commercial reality, they were accepting

00:21:06.140 --> 00:21:08.859
smaller, immediate profits to build a much larger,

00:21:08.920 --> 00:21:11.339
more valuable platform for the future. The human

00:21:11.339 --> 00:21:13.539
capital figures also reflect this challenge.

00:21:14.420 --> 00:21:19.180
3 ,100 employees globally in 2025. I mean, just

00:21:19.180 --> 00:21:22.059
think about the organizational complexity. Managing

00:21:22.059 --> 00:21:25.680
3 ,100 people across dozens of previously independent,

00:21:25.960 --> 00:21:28.740
highly scientific firms. You're not just buying

00:21:28.740 --> 00:21:32.420
patents. You're buying teams, expertise, infrastructure

00:21:32.420 --> 00:21:34.859
that all has to be standardized. It requires

00:21:34.859 --> 00:21:37.319
a really efficient integration process. A highly

00:21:37.319 --> 00:21:39.819
efficient and repeatable one. And just to mention

00:21:39.819 --> 00:21:41.680
the leadership that oversaw this stabilization

00:21:41.680 --> 00:21:45.480
phase. The key people in 2025 are Kim Kelderman

00:21:45.480 --> 00:21:49.099
as CEO, James Hipple as the CFO, and Robert V.

00:21:49.119 --> 00:21:51.099
Baumgartner as chairman. And that leadership

00:21:51.099 --> 00:21:53.119
continuity is so important for steadying the

00:21:53.119 --> 00:21:54.779
ship after a period of such rapid expansion.

00:21:55.019 --> 00:21:57.539
You need that stable financial management. Finally,

00:21:57.599 --> 00:21:59.420
their market significance is just undeniable

00:21:59.420 --> 00:22:02.420
now, being traded on Nasdaq and crucially being

00:22:02.420 --> 00:22:05.319
an S &P 500 component. That confirms it. It puts

00:22:05.319 --> 00:22:07.220
them among the largest, most influential public

00:22:07.220 --> 00:22:09.740
companies in the U .S. And being in the S &P

00:22:09.740 --> 00:22:12.839
500 means institutional investors see them not

00:22:12.839 --> 00:22:16.759
as some speculative biotech play, but as a core

00:22:16.759 --> 00:22:19.920
reliable piece of the modern industrial and pharmaceutical

00:22:19.920 --> 00:22:23.019
infrastructure. They successfully aggregated

00:22:23.019 --> 00:22:25.660
value by owning the entire workflow. From the

00:22:25.660 --> 00:22:28.279
initial regent to the final sophisticated instrument.

00:22:28.539 --> 00:22:31.319
That's it. So if we summarize this entire journey,

00:22:31.460 --> 00:22:34.140
it really is a textbook case study in corporate

00:22:34.140 --> 00:22:36.599
transformation. Absolutely. Going from a small

00:22:36.599 --> 00:22:39.099
regional player, research and diagnostic systems

00:22:39.099 --> 00:22:42.940
in 1976, to the multi -billion dollar, highly

00:22:42.940 --> 00:22:46.250
focused biotechnology of 2025. And this entire

00:22:46.250 --> 00:22:48.490
monumental pivot was driven by that executive

00:22:48.490 --> 00:22:52.190
change in 2013 and a relentless decade of M &A.

00:22:52.380 --> 00:22:54.900
And the key takeaway for you, the learner, is

00:22:54.900 --> 00:22:57.079
that the value of a company in this space is

00:22:57.079 --> 00:22:59.420
often defined not just by its internal R &D,

00:22:59.539 --> 00:23:02.099
but by its ability to strategically acquire specialized

00:23:02.099 --> 00:23:05.119
IP and platforms. Speed was everything. Paramount.

00:23:05.220 --> 00:23:06.960
They didn't try to invent the protein simple

00:23:06.960 --> 00:23:09.400
automation or the exosome liquid biopsy from

00:23:09.400 --> 00:23:11.519
scratch. They just bought the innovators. They

00:23:11.519 --> 00:23:13.960
focused on creating those comprehensive end -to

00:23:13.960 --> 00:23:16.700
-end solutions. And by making those massive platform

00:23:16.700 --> 00:23:19.640
acquisitions, they became a one -stop shop, ensuring

00:23:19.640 --> 00:23:21.299
that once a customer was in their ecosystem,

00:23:21.819 --> 00:23:23.900
They stayed there. And their story shows a powerful

00:23:23.900 --> 00:23:27.279
reality. In an industry moving as fast as this

00:23:27.279 --> 00:23:30.160
one, innovation is often achieved through aggressive

00:23:30.160 --> 00:23:33.099
consolidation. And they manage the immense financial

00:23:33.099 --> 00:23:36.019
risk of that speed by using cash for stability

00:23:36.019 --> 00:23:38.380
and those complex earnouts for the frontier tech.

00:23:38.599 --> 00:23:41.380
Which leaves us with a final provocative thought.

00:23:41.640 --> 00:23:44.359
Given Biotechny's consistent track record of

00:23:44.359 --> 00:23:46.700
buying these very specific high -tech firms,

00:23:47.019 --> 00:23:49.819
gene editing, exosomes, single -cell spatial

00:23:49.819 --> 00:23:52.420
tech bragement, We know where the cutting edge

00:23:52.420 --> 00:23:55.779
is. The question now becomes, what specialized

00:23:55.779 --> 00:23:58.480
piece of lab or diagnostic technology, maybe

00:23:58.480 --> 00:24:01.380
an AI -driven image analysis or rapid point -of

00:24:01.380 --> 00:24:04.000
-care testing, might be the next target for consolidation

00:24:04.000 --> 00:24:06.599
in this market? And which small, innovative company

00:24:06.599 --> 00:24:08.900
might be about to get that $300 million cash

00:24:08.900 --> 00:24:11.180
offer with a massive earn -out tacked on? The

00:24:11.180 --> 00:24:13.880
consolidation of the space never ends. Keep watching

00:24:13.880 --> 00:24:17.299
those emerging tech startups. Biotechni and its

00:24:17.299 --> 00:24:19.700
competitors certainly are. It's all the time

00:24:19.700 --> 00:24:22.079
we have for this deep dive. thank you for sharing

00:24:22.079 --> 00:24:24.420
your sources my pleasure and we look forward

00:24:24.420 --> 00:24:25.480
to going deep on the next one